Format

Send to

Choose Destination
Trends Mol Med. 2011 Feb;17(2):108-16. doi: 10.1016/j.molmed.2010.10.008. Epub 2010 Nov 26.

B cell responses to HIV-1 infection and vaccination: pathways to preventing infection.

Author information

1
Duke Human Vaccine Institute and the Duke Center for AIDS Research, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA. ayne002@mc.duke.edu

Abstract

The B cell arm of the immune response becomes activated soon after HIV-1 transmission, yet the initial antibody response does not control HIV-1 replication, and it takes months for neutralizing antibodies to develop against the autologous virus. Antibodies that can be broadly protective are made only in a minority of subjects and take years to develop--too late to affect the course of disease. New studies of the earliest stages of HIV-1 infection, new techniques to probe the human B cell repertoire, the modest degree of efficacy in a vaccine trial and new studies of human monoclonal antibodies that represent the types of immune responses an HIV-1 vaccine should induce are collectively illuminating paths that a successful HIV-1 vaccine might take.

PMID:
21112250
PMCID:
PMC3053087
DOI:
10.1016/j.molmed.2010.10.008
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center